CSO and Co-founder @ INF Technology (August 2022 - July 2023)
Chief Technology Officer @ (December 2020 - August 2022)
Chief Scientific Officer and Co-Founder @ Forkhead BioTherapeutics Inc (February 2018 - December 2020)
Scientific Team Leader and Principal Research Scientist @ Eli Lilly and Company (January 2016 - February 2018)
Group Leader and Associate Research Director @ Eli Lilly and Company (September 2014 - January 2016)
Group Leader and Principal Scientist II @ Eli Lilly and Company (December 2011 - September 2014)
Senior Research Biologist @ Merck Research Laboratories, Diabetes and Obesity (December 2008 - December 2011)
Associate Research Scientist @ (June 2008 - December 2008)
Postdoctoral Research Scientist @ (September 2004 - May 2008)
Hua Lin Education
University of Michigan
PhD (Molecular, Cellular, and Developmental Biology)
1998-2004
Peking University
BS (Cell Biology and Genetics)
1994-1998
The High School Affiliated to Renmin University of China 1989-1994
Hua Lin Skills
Drug Discovery
Animal Models
In Vivo
Diabetes
Cell Biology
In Vitro
Assay Development
Biochemistry
Western Blotting
Cell Culture
Molecular Biology
Molecular Cloning
Immunohistochemistry
Genetics
ELISA
Microsoft Office
Leadership
Project Management
Science
Program Management
Strategy
Microsoft Excel
Research
R&d
Biotechnology
GLP
Cancer Research
Chemistry
Fatty Acids
Materials Management
Mouse
Peptides
Target Identification
Disease
ERD
Human Resources
Propagation
KnockoutJS
Surveying
Data Analysis
Responsibility
Tao
Keystone
Proliferation
Strategies
Differential
Internal Controls
Recruiting
Tissue
Presentations
Stimulation
Holland
Local Area Network
Muscle
Apoptosis
Wang
Cancer
Licensing
Spray
Evaluation
Central Nervous System
Molecular
Cross Functional Team Leadership
Characterization
Exploratory
Undergraduate
IC
Endocrine
Supervision
Software Lifecycle
Glucose
Bone
Vendors
Execution
Scientific
Mouse Models
Laboratory
Transgenic Mice
Travel
China
Treatment
Failure
IBM AS/400
Obesity
Insulin Resistance
Sensors
Sympathetic
Signalling
Analysis
Compensation
Scientists
Internal Audit
Customer Service
Life Sciences
Portfolio Development
Mechanism
CPE
R
Nature
Research Projects
Optimization
Arbor
Clinical Development
Hormones
New York
Management
Diet
Academic
Robust
Medicine
In Licensing
Drosophila
Impairment
Toxicology
Data Transformation
Factor
Scholarships
Initiation
Diabetic
Europe
Cell
Hunting
Coordination
C
Lead Change
Design
Panasonic
Investigation
Symposium
Site Operations
Regulations
Moa
LIN
Adobe Contribute
GI
American
Resistance
Google Groups
Usa
Academic Institutions
Portfolio
Business Insights
Key Capabilities
Assessment
Cellular Communications
Exploring
Ex Vivo
Shanghai
Metabolism
Launching
Biology
Mechanisms
Translational Research
Rescue
Lipid Metabolism
Mass Spectrometry
Acid
Validation
Energy Balance
Gao
Neurons
Short
Clinical Research
Pathogenesis
Expression
Coordinated
NX Unigraphics
Cho
DJ
Energy
Integrative
Cros
Bone Density
Ml
Atherosclerosis
Sage Act
Dependent
Endocrinology
Ducation
Beijing
Facilitation
Students
Cao
Thompson
Pharmacology
Developmental Biology
Physiology
Conferences
Mass
Survival Analysis
Pancreatic
PE
Engagement
Golang
Thesis
Molecular Genetics
Brain
Human Nutrition
Chain
Weight
Insulin
Hv
Training
Backgrounds
Controlling
Therapists
Hua Lin Summary
Hua Lin, based in West Palm Beach, FL, US, is currently a Chief Scientific Officer at Genuiti Therapeutics. Hua Lin brings experience from previous roles at Alpha Young, INF Technology, BioFront Therapeutics and Forkhead BioTherapeutics Inc. Hua Lin holds a 1998 - 2004 PhD in Molecular, Cellular, and Developmental Biology @ University of Michigan. With a robust skill set that includes Drug Discovery, Animal Models, In Vivo, Diabetes, Cell Biology and more. Hua Lin has 1 emails and 2 mobile phone numbers on RocketReach.
Looking for a different Hua Lin?
Find contact details for 700 million professionals.